Redeye comments on Ultimovacs reporting NIPU top-line data, communicating that the phase II trial had not met its primary PFS endpoint. However, local PFS assessments contrastingly showed a statistically significant PFS improvement in the treatment group. Further, NIPU seemed to feature a positive yet immature OS trend in the treatment group. Overall, we judge that the readout created more confusion than clarity. We believe the final word on NIPU has not been said yet, though the readout did not represent a ‘blue sky’ scenario.